2016至2021年欧洲药品管理局评估的风险最小化措施有效性研究综述
该研究回顾了2016至2021年欧洲药品管理局药物警戒风险评估委员会评估的上市后安全性研究,发现93项研究中仅约60%对风险最小化措施有效性做出结论,其中82.1%判定为有效,且研究特征与结论间无明确差异。
要点
- 约40%的上市后安全性研究未对风险最小化措施有效性做出结论
- 做出结论的研究中82.1%判定风险最小化措施有效
- 研究特征与有效性结论间仅见微小差异,需进一步研究无结论原因
核心结论
- 4成评估风险最小化措施影响的研究未对有效性做出结论。
- 研究特征与结论间无明确差异,需额外研究理解无结论原因。
主要发现
- 62.4%的PASS旨在测量医护人员对风险最小化措施的认知、知识和行为。
- 67.7%的PASS使用原始数据,24.7%使用二手数据源,7.5%两者兼用。
- 横断面设计最常用(77.4%),其次为队列设计(29.0%)。
- 近40%的PASS未对风险最小化措施有效性做出结论。
- 做出结论的60%中,82.1%判定为有效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The European Medicines Agency (EMA) supervises medicines' safe and effective use throughout the product's life cycle by, for example, monitoring the implementation of risk minimization measures (RMMs). Limited information is available on factors associated with effectiveness of RMMs. This study reviews post-authorization safety studies (PASS) evaluating the effectiveness of RMMs assessed by the Pharmacovigilance Risk Assessment Committee (PRAC) between 2016 and 2021. PASS assessment reports finalized by PRAC between January 1, 2016, and December 31, 2021, were compiled from non-public EMA databases and PASS characteristics were extracted. Of the 93 PASS included, 62.4% aimed to measure healthcare professionals' awareness, knowledge, and behavior regarding RMMs. There were 67.7% of the 93 PASS that used primary data, 24.7% used secondary data sources, and 7.5% used both. A cross-sectional study design was most frequently applied (77.4%), followed by a cohort study design (29.0%). Nearly 40% of the included PASS did not render a conclusion on RMM effectiveness. Of the 60% that did render a conclusion, 82.1% were deemed effective. Only minor differences in characteristics were found when stratified by outcome (i.e., effective RMM, ineffective RMM, and no conclusion on RMM effectiveness). To conclude, 4 out of 10 PASS assessing impact of RMMs did not render a conclusion on RMM effectiveness. No clear differences in PASS characteristics were found in relation to their outcomes, indicating that additional research is needed to understand better the underlying reasons for PASS being inconclusive.
引用
- Grupstra RJ, Goedecke T, Scheffers J, et al. Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021. Clin Pharmacol Ther. 2023. PMID: 37634124. doi:10.1002/cpt.3034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。